IgMXVIIIA2C2,

Elizabeth S York1, Benjamin D Dratch2, Jasmine Ito3

  • 1Department of Pediatrics, Stanford University, Palo Alto, California, USA; Department of Pediatrics, Emory University, Atlanta, Georgia, USA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

概括

在血友病A中对因子VIII (FVIII) 的持久性IgM抗体似乎不会影响有害IgG抑制剂的发展. 这些IgM抗体结合特定的FVIII域,但不会改变抑制剂的形成.